Erysipelas medical therapy: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 1: Line 1:
__NOTOC__
__NOTOC__
{{Erysipelas}}
{{Erysipelas}}  
{{CMG}}; {{AE}} {{Maliha}}
{{CMG}}; {{AE}} {{Maliha}} {{LRO}}


==Overview==
==Overview==

Revision as of 13:56, 15 September 2016

Erysipelas Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Erysipelas from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Electrocardiogram

X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Erysipelas medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Erysipelas medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Erysipelas medical therapy

CDC on Erysipelas medical therapy

Erysipelas medical therapy in the news

Blogs on Erysipelas medical therapy

Directions to Hospitals Treating Erysipelas

Risk calculators and risk factors for Erysipelas medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Maliha Shakil, M.D. [2] Luke Rusowicz-Orazem, B.S.

Overview

The mainstay of therapy for erysipelas is antimicrobial therapy. Pharmacologic therapy for erysipelas includes either Penicillins, Erythromycin, or Cephalosporins. Empiric therapy for facial erysipelas includes either Vancomycin, Daptomycin or Linezolid.

Medical Therapy

Antimicrobial Regimen

  • 1. Adults
  • 2. Pediatrics
  • Preferred regimen (1): Penicillin 25 to 50 mg/kg/day PO tid or qid
  • Preferred regimen (2): Amoxicillin 25 to 50 mg/kg/day PO tid
  • Preferred regimen (3): Erythromycin 30 to 50 mg/kg/day PO bid to qid
  • Preferred regimen (4): Ceftriaxone 50 to 75 mg/kg/day IV q12-24h
  • Preferred regimen (5): Cefazolin 100 mg/kg/day IV q8h
  • Facial erysipelas[2]
  • 1. Causative pathogens
  • Staphylococcus aureus
  • Streptococcus spp. (Group A, B, C, & G)
  • Enterobacteriaceae
  • Clostridium spp.
  • 2. Empiric antimicrobial therapy

References

  1. Stevens DL, Bisno AL, Chambers HF, Dellinger EP, Goldstein EJ, Gorbach SL; et al. (2014). "Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the infectious diseases society of America". Clin Infect Dis. 59 (2): 147–59. doi:10.1093/cid/ciu296. PMID 24947530.
  2. Gilbert, David (2015). The Sanford guide to antimicrobial therapy. Sperryville, Va: Antimicrobial Therapy. ISBN 978-1930808843.

Template:WS Template:WH